Terran Biosciences Announces Licensing Agreement with Columbia University for Exclusive Worldwide Rights to Proprietary CNS Biomarker Software Platform

NEW YORK, March 16, 2022 /PRNewswire/ — Terran Biosciences, Inc. (“Terran”), a biotechnology platform company dedicated to developing transformational therapies and technologies for neurological and psychiatric diseases, has entered into an agreement with Colombia University (“Columbia”) and the Research Foundation for Mental Hygiene (“RFMH”), to obtain exclusive worldwide rights to develop and commercialize Columbia’s proprietary CNS biomarker software platform and patent portfolio.

The fundamental algorithms were originally developed by a team of Colombia doctors, neuroscientists and software engineers, led by Guillermo HorgaMD, PhD, and Clifford Cassidy, doctorate. This new technology has already demonstrated promising clinical applications in several studies covering a number of indications, including schizophrenia, Parkinson’s disease, Alzheimer’s disease, major depression, substance abuse and post-stress stress disorder. trauma (PTSD).

Based on this data, Terran further develops the algorithms by incorporating them into Terran’s cloud-based software as a Medical Device Platform (SaMD). Terran also sponsors additional clinical research studies at RFMH and Colombia, and expands the data set, indications of interest and patent portfolio. Terran aims to advance this platform to help establish non-invasive, cost-effective solutions for patients with neurological and psychiatric conditions.

dr. sam clarkCEO of Terran, commented “The team at Colombia and RFMH has done an incredible job in building this software platform to help solve very difficult questions around the identification and measurement of key brain biomarkers in neuropsychiatry. We look forward to continuing this research collaboration to advance this work and expand access to this powerful technology.”

dr. Guillermo Horgaassociate professor of clinical psychiatry at Colombia University Vagelos College of Physicians and Surgeons, said, “We are excited to continue collaborating with the Terran team to take this work even further and explore its capabilities in a number of different disease states and applications.

About Terran Biosciences, Inc.

Terran is a biotechnology platform company developing a portfolio of therapies and technologies for patients with neurological and psychiatric diseases. Backed by a number of life science and technology investors, Terran has built a technology-driven, CNS-focused drug development platform, and is rapidly advancing a number of actives in advanced phase, which include new therapies based on psychedelics.

Earth Contact
Investor Relations:
[email protected]

Media:
[email protected]

SOURCE Terran Biosciences, Inc.

Back To Top